|
Home | Medical-Newswire.Com:
|
(EMAILWIRE.COM, November 04, 2009 ) New York, NY - Just two years ago, the therapeutic antibodies market enjoyed industry-wide sales of $7.3 billion. This market is expected to grow by 30% annually and reach $22 billion by 2010. Cancer dominates this market because the rewards of success dwarf most other ventures on the planet. Chemistry World magazine correctly says, “Cancer is a huge market.” It is an unfortunate fact, but a fact nonetheless.
Three-Step Marketing Plan
Being a small company, MabCure is marketing their invention in a very smart way. There are three broad ways to maximize maximize revenue potential. The first is using this technology in diagnosing or screening for the three illnesses. This is where there is, naturally, instant overnight demand. Second is in the imaging of the illnesses. This simply means a physical picture a doctor looks at to analyze your condition. They can now see the illness. This is extremely useful by doctors. Third, is in developing new drugs that can defeat this illness in a quicker, more efficient way. “The market potential of these new drugs is in the multi-billion dollar range,” says MabCure.
MabCureÂ’s strategy is to first concentrate on deadly, fast-growing cancers where demand is instant, huge and growing. ItÂ’s a sound, realistic business objective.
Time Magazine Reports
Time Magazine said that, “We are in the midst of a complete and profound change in our development of cancer treatments…This was all a dream five years ago…doctors will be given tools for detecting the earliest stages of many cancers – in some cases when they are only a few cells strong – and suppressing them before they have a chance to progress to malignancy…”
MabCure Inc. currently trades at about $1.00 per share on the Over the Counter Bulletin Board, and developments are happening fast!
Disclosure: All material herein was prepared by Keros Capital Inc. (Keros) based upon information believed to be reliable. The information contained herein is not guaranteed by Keros to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Keros is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.keroscapital.com or mentioned herein. Keros has been compensated seven thousand five hundred dollars for this advertising effort. Keros may receive additional compensation for future advertisements. Keros affiliates, officers, directors and employees may own shares and may buy and sell additional shares of the company mentioned herein and may profit in the event those shares rise in value. Keros will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market. Copyright 2007 by Keros Capital. All rights reserved. This publication or part thereof may not be duplicated or reprinted without the written permission of the Publisher. Facsimile including photocopy(s) is strictly forbidden, except for facsimile correspondence between Keros Capital. If this publication contravenes any securities laws and/or regulations, the securities regulations of the country will prevail. In this event, this publication must be discarded immediately. Anyone not wishing to receive future Keros Capital Investor Reports should email us at opt-out@keroscapital.com
MabCure Inc.
Jim Mav
908-464-1747
jimmav@keroscapital.com 
Source: EmailWire.com
|
|
|
|
